摘要
目的:寻找预后不良的三阴乳腺癌(TNBC)潜在的预后分子标志物。方法:从GEO数据库下载GSE76275的基因表达谱。该微阵列由67个非TNBC和198个TNBC共265个样本组成。综合分析所有P<0.05和倍数变化≥1或≤-1的差异表达基因(DEG)。结果:鉴定出138个上调基因和210个下调基因,并进行基因本体论(GO)、京都基因与基因组途径百科全书(KEGG)富集分析。这些基因主要参与细胞增殖、蛋白水解、蛋白质同源二聚化活性、钙离子结合、序列特异性DNA结合、细胞周期和PPAR信号通路的生物学过程。利用蛋白质相互作用网络鉴定了10个中枢基因,利用GEPIA进一步进行生存分析,筛选出BIRC5为TNBC的预后关键基因。结论:鉴定出的这些途径和基因可以帮助理解TNBC的发展机制;BIRC5可能是TNBC治疗的潜在靶点。
Objective:To find potential molecular prognostic markers for triple-negative breast cancer(TNBC)with poor prognosis.Methods:The gene expression profile of GSE76275 from GEO database was downloaded.The microarray consisted of 265 samples,including 67 non-TNBC and 198 TNBC.Comprehensive analysis of all differentially expressed genes(DEG)with P<0.05 and fold change≥1 or≤-1 was performed.Results:One hundred and thirty-eight up-regulated genes and 210 down-regulated genes were identified,and gene ontology(GO)and Kyoto Encyclopedia of Genes and Genome Pathways(KEGG)enrichment analysis were performed.These genes were mainly involved in the biological processes of cell proliferation,proteolysis,protein homodimerization activity,calcium ion binding,sequence-specific DNA binding,cell cycle and PPAR signaling pathway.The protein interaction network was used to identify 10 central genes,and GEPIA was used for further survival analysis.BIRC5 was screened out as a key prognostic gene for TNBC.Conclusion:The identified pathways and genes can help understand the development mechanism of TNBC.BIRC5 may be a potential target for TNBC treatment.
作者
王一晴
曾冬阳
龚智逊
王雅阁
杨作磊
WANG Yiqing;ZENG Dongyang;GONG Zhixun;WANG Yage;YANG Zuolei(Graduate School,Hainan Medical College, Haikou 571199, China;Department of Radiotherapy, the Second Affiliated Hospital of Hainan Medical College, Haikou 570311, China;Department of Thyroid and Breast Surgery, the Second Affiliated Hospital of Hainan Medical College, Haikou 570311, China)
出处
《东南大学学报(医学版)》
CAS
2022年第2期241-245,共5页
Journal of Southeast University(Medical Science Edition)
基金
海南省卫生计生行业科研项目(20A200399)。
关键词
三阴乳腺癌
预后标志物
BIRC5
triple-negative breast cancer
prognostic markers
BIRC5